Daptomycin may be a feasible treatment option for patients with Methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection when vancomycin MICs are 1.5-2.0 μg/mL.
HIV Prophylaxis with twice-daily lopinavir/ritonavir was well tolerated in high-risk neonates without adverse drug events, as reported at IDWeek 2013.
Girls 9-13 years with HIV who received the quadrivalent human papillomavirus vaccine (qHPV) had significantly lower peak geometric mean titers (GMT) vs. same-aged girls without HIV infection, a study presented at IDWeek 2013 has found.
The completion rate of a 12-dose, 3-month isoniazid/rifapentine (3HP) regimen in this study (83.7%) is comparable to its completion rate in Study 26 (82.1%), and is significantly higher than the average 55.0% completion rate for the 9-month isoniazid regimen that was reported in Arkansas for the past 5 years, according to results presented at IDWeek 2013.
Pyrazinamide is safe in elderly patients >80 years old not experiencing malnourishment, low-grade ADL, and previously elevated liver enzymes, as presented by Ryutaro Tanizaki, MD, from the National Center for Global Health and Medicine, Tokyo, Japan at IDWeek 2013.
Fidaxomicin was highly effective in patients with cancer treated for the first episode of C. difficile infection (CDI) after failure of standard therapy and in patients with recurrent CDI, results of a study presented at IDWeek 2013.
Distribution patterns of species was similar in hospital-associated (HA) and community-associated (CA) intra-abdominal infections (IAI), according to study results presented at IDWeek 2013.
In HIV-seropositive patients on antiretroviral therapy (ART) with non-infectious diarrhea, crofelemer 125mg twice daily was well tolerated with a low incidence of adverse events and no clinical deterioration of immune status, study investigators reported at IDWeek 2013.
Once-daily oral combination of daclatasvir (DCV) + sofosbuvir (SOF) with or without ribavirin (RBV) achieved sustained virologic response (SVR) in chronic HCV GT1 infected patients with prior telaprevir (TVR) or boceprevir (BOC) + peginterferon/ribavirin treatment failures.
Antifungal prophylaxis is associated with significant reduction in induction mortality rates in pediatric patients with acute myeloid leukemia (AML) and reduced supportive care resources utilization.
Hepatitis B virus (HBV) vaccine response status was not associated with post-combination antiretroviral therapy (cART) CD4 gains at 1-year among those with virologic suppression, a study concluded at IDWeek 2013.
Combination fluoroquinolone plus probiotic for the eradication of Quiescent Intracellular Reservoirs (QIRs) resulted in a decrease of recurrent urinary tract infections (UTI) in pediatric patients.
In methicillin-sensitive Staphylococcus aureus (MSSA) bloodstream infections (BSI), cefazolin may have similar rates of clinical cure as oxacillin, including treatment of high-burden infections, according to IDWeek 2013.
Investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y elicited similar responses in adolescents to those anticipated from the constituent ACWY and B vaccines, a study presented at IDWeek 2013 has found.
A systematic review of 30 randomized controlled trials (RCTs) showed the 5-nitroimidazoles demonstrated efficacy in the treatment of giardiasis, a study concluded at IDWeek 2013.
Similar achievement of >20% reduction of lesion size was noted in patients treated with oritavancin and vancomycin for acute bacterial skin and skin structure infections at Hours 48 and 72, a study at IDWeek 2013 has found.
Resistance patterns for antibiotics used against Gram-negative bacteria over the past 12 years are linked to initial double-coverage of suspected Gram-negative species, a study reported at IDWeek 2013.
A single dose of benzathine penicillin G is sufficient to treat patients with HIV infection and early syphilis, a study presented at IDWeek 2013 has found.
Patients with ventilator-associated pneumonia (VAP) due to methicillin-resistant Staphylococcus aureus (MRSA) achieved an earlier time to clinical stability when treated with linezolid vs. vancomycin, results of the IMPACT-HAP study reported at IDWeek 2013.
ICU patients who receive more than 24 hours of inappropriate antibiotics have a higher mortality rate; this risk factor is not observed with inappropriate antibiotic use within the first 24 hours, a study concluded at IDWeek 2013.
Ceftolozane/tazobactam exhibited potent antimicrobial activity when tested against Pseudomonas aeruginosa isolates from US medical centers, including multidrug-resistant strains, a study reported at IDWeek 2013.
In a cohort of pregnant women, no associations were found between the 2010-2011 seasonal influenza infection or vaccination and four common maternal outcomes—gestational hypertension, preeclampsia/eclampsia, gestational diabetes, and chorioamnionitis—a prospective study concluded at IDWeek 2013.
Penicillins may be used with low risk of treatment failure for patients with community-acquired pneumonia (CAP), a case-control study reported at IDWeek 2013 has found.
Treatment with sofosbuvir + peginterferon alfa-2a/ribavirin for 12 weeks in treatment-naïve, HIV/HCV co-infected patients led to a highly effective sustained virologic response rate, results of a study presented at IDWeek 2013.
Week 48 "snapshot analysis" finds two single tablet regimens non-inferior for virologic suppression in treatment-naïve patients with HIV-1 infection, the STaR study reported at IDWeek 2013.
Patients with HIV-1 treated with rilpivirine/emtricitabine/tenofovir DF once-daily single-tablet regimen maintained virologic suppression at 48 weeks regardless of initiation time.
Researchers did not observe a difference in recurrent infections when treated with either clindamycin or trimethoprim-sulfamethoxazole (TMP-SMX) in patients with uncomplicated skin and soft tissue infections (uSSTIs), according to results presented at IDWeek 2013.
Significantly high rates of premature treatment discontinuation was observed in patients treated with either nafcillin or cefazolin, with high rates of drug-related adverse events (DRAE) occurring with nafcillin treatment, as presented at IDWeek 2013.
Elvitegravir/cobicistat/emtricitabine/tenofovir DF was well-tolerated and safe compared with efavirenz/emtricitabine/tenofovir DF in treatment-naïve Black patients with HIV infection, a study presented at IDWeek 2013 has found.
Renal impairment of any kind had no significant impact on the efficacy of daptomycin vs. vancomycin in the treatment of MRSA bacteremia, a study presented at IDWeek 2013 has concluded.